secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2023-02-06T23:59:59+00:00
Accession:  0001213900-23-008236
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01, 5.07, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity faces SEC probe into Dovitinib NDA; key shareholder proposals fail; board non-compliant with Nasdaq
--------------------------------------------------------------------------------

- SEC investigation launched Jan 2023; documents requested on Dovitinib NDA communications with FDA.
- Proposals to increase authorized shares to 150M and effect reverse stock split did not pass.
- Board has only 2 independent directors after resignation of Soren G. Jensen; Nasdaq rules violated.
- Series B Preferred Stock automatically redeemed after annual meeting on Feb 3, 2023.
- Company has until the earlier of next annual meeting or Feb 4, 2024 to regain listing compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390023008236/0001213900-23-008236-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390023008236/ea172721-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-008236

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer